哈佛学生靠医疗“ChatGPT”，成了亿万富翁

Core Insights - OpenEvidence is a rapidly growing AI-driven clinical decision support platform that has gained significant traction among U.S. physicians, with over 100,000 daily users, up from a few thousand just a year ago [2][4] - The platform addresses the challenge of rapidly evolving medical knowledge, allowing doctors to quickly access the latest evidence-based information [2][6] - OpenEvidence's unique business model bypasses traditional healthcare software sales, offering free access to individual doctors and monetizing through targeted advertising [19][20] Company Overview - OpenEvidence was founded by Daniel Nadler and Zachary Ziegler, both Harvard alumni, with Nadler previously selling his financial AI company Kensho for approximately $550 million [22][25] - The platform has achieved a valuation of $3.5 billion within three years of its inception, with significant funding from top venture capital firms [25][28] - OpenEvidence's mission is to organize and expand global medical knowledge, providing verified physicians with quick access to relevant clinical information [6][10] User Engagement - The platform has registered over 430,000 doctors, covering over 40% of practicing physicians in the U.S., with a monthly user growth rate of 65,000 [4][5] - OpenEvidence processes approximately 850,000 clinical inquiries monthly, showcasing its high usage frequency among healthcare professionals [5][10] - The platform's core functionality includes intelligent search and instant Q&A, providing precise answers with authoritative citations in just 5-10 seconds [9][10] Technological Innovation - OpenEvidence utilizes a specialized AI model that avoids the common pitfalls of hallucination by relying on authoritative sources such as FDA and CDC data [12][13] - The platform has integrated advanced features like the DeepConsult AI agent, which can autonomously analyze hundreds of studies and generate comprehensive reports for physicians [10][15] - OpenEvidence is the first AI system to achieve a perfect score on the U.S. Medical Licensing Examination (USMLE), highlighting its advanced capabilities [14] Market Strategy - The company employs a "freemium + advertising" model, similar to early Google, to build a large user base before monetizing through targeted ads [19][20] - OpenEvidence's advertising strategy is designed to maintain trust among users by clearly distinguishing between organic results and advertisements [20] - The platform's approach has created a strong network effect, establishing itself as a standard within the medical community [19][20] Competitive Landscape - OpenEvidence operates in a competitive environment, with emerging startups like DynaMed and Hippocratic AI also focusing on clinical decision support tools [28][29] - The failure of IBM's Watson Health serves as a cautionary tale, emphasizing the importance of practical application and user trust in the success of medical AI solutions [28]